|1/20/2021||Orion publishes Financial Statement Release for 2020 on Tuesday 9 February 2021|
|1/18/2021||Orion Animal Health and Vetoquinol expand collaboration – Vetoquinol to distribute Orion’s Clevor® in the USA and Orion to distribute Drontal® and Profender® products in Finland, Hungary and Romania|
|11/10/2020||Orion invests EUR 17 million in its production plants in Turku|
|11/4/2020||Orion Research Foundation grants 1 014 400 euros for research in 2021|
The 2021 Annual General Meeting of Orion Corporation is planned to be held on 25 March 2021 in Helsinki.
|1/12/2021||Recommendation by the Nomination Committee concerning the Board of Directors to be elected by the 2021 AGM of Orion Corporation|
|12/18/2020||8,242 Orion Corporation A shares converted into B shares|
|10/29/2020||Prosecutor pressed charges against a member of Orion’s Board of Directors for a suspected securities market offence – the suspected offence is not related to Orion|
|10/21/2020||Composition of the Nomination Committee of Orion Corporation|
Orion will publish Financial Statement Release for January-December 2020 on Tuesday, 9 February 2021 approximately at 12.00 noon EET. The release and related presentation material as well as link to live webcast and conference call info will be available here.
The product and service portfolio of Orion includes a variety of human pharmaceuticals, veterinary drugs, APIs and contract manufacturing.
Orion is the largest employer in the Finnish pharmaceutical industry. It is considered to be a good and reliable employer, which is also indicated by its lower-than-average employee turnover.